CD80 and cancer: Current efforts to improve the efficacy of cancer immunotherapy are mainly focused on reversing T cell exhaustion by exploiting pathways such as the PD-L1/PD-1 signaling pathway and the CD80/-86/CTLA4 pathway (5).